Heron Therapeutics | HRTX - Selling And Administration Expenses


Heron Therapeutics reported $23.74M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
ALKERMES USD 187.2M 15.43M Dec/2025
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amarin USD 18.97M 1.03M Dec/2025
ANI Pharmaceuticals USD 82.79M 6.13M Dec/2025
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Eisai JPY 111.72B 7.86B Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Esperion Therapeutics USD 39.42M 456K Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Merck USD 2.67B 180M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 83.88M 7.99M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Surmodics USD 11.4M 3.18M Jun/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Veracyte USD 43.31M 8.43M Dec/2025
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026